Ann: $15m Placement Completed-Including US Cornerstone Investor, page-3

Placement to Raise $15m with Cornerstone Investment
by Leading USA Biotech Investor

• $15m Placement to fund further development of Actinogen Medical’s lead drug, Xanamem, with
cornerstone investment from leading USA biotech investor Biotechnology Value Fund, L.P. and certain
of its affiliates (BVF)
• Placement price of $0.05 per share represents an 13.4% premium to the 5-day VWAP
• BVF to become the largest shareholder following completion of the Placement with a 19.9% holding
• Investment from significant biotech investor provides validation of Xanamem’s innovative potential
in the treatment of Alzheimer’s disease and other conditions associated with cognitive impairment
• Placement coincides with positive outcome of XanADu Interim Analysis
• Share Purchase Plan at $0.05 per share to raise up to a further $2m, bringing the total capital raised
to a maximum of $17m
• Shareholder meeting to be held for approvals required under this Placement
• Investor conference call with key members of management and the Company’s Clinical Advisory Board
to take place on Wednesday 30th of May at 10:30am AEST